266 related articles for article (PubMed ID: 23124151)
1. Mixed-type multicentric Castleman's disease developing during a 17-year follow-up of sarcoidosis.
Awano N; Inomata M; Kondoh K; Satake K; Kamiya H; Moriya A; Ando T; Kumasaka T; Takemura T; Takeuchi K; Ikushima S
Intern Med; 2012; 51(21):3061-6. PubMed ID: 23124151
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.
Kawabata H; Kotani S; Matsumura Y; Kondo T; Katsurada T; Haga H; Kadowaki N; Takaori-Kondo A
Intern Med; 2013; 52(13):1503-7. PubMed ID: 23812199
[TBL] [Abstract][Full Text] [Related]
3. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
[TBL] [Abstract][Full Text] [Related]
4. Mixed connective tissue disease associated with multicentric Castleman's disease.
Nanki T; Tomiyama J; Arai S
Scand J Rheumatol; 1994; 23(4):215-7. PubMed ID: 8091149
[TBL] [Abstract][Full Text] [Related]
5. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.
Saiki R; Katayama K; Hirabayashi Y; Oda K; Fujimoto M; Murata T; Nakajima A; Dohi K
BMC Nephrol; 2021 Jun; 22(1):216. PubMed ID: 34107915
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab).
Otani N; Morishita Y; Oh I; Saito O; Takemoto F; Muto S; Kusano E
Intern Med; 2012; 51(11):1375-8. PubMed ID: 22687845
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman's disease.
Ebisawa K; Masamoto Y; Tokushige J; Nishi H; Honda K; Hinata M; Toyama K; Nangaku M; Kurokawa M
Ann Hematol; 2019 Aug; 98(8):1995-1997. PubMed ID: 30761408
[No Abstract] [Full Text] [Related]
8. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
[TBL] [Abstract][Full Text] [Related]
9. [Evans syndrome complicated with multicentric Castleman disease successfully treated with tocilizumab].
Nakayama H; Kikuchi T; Abe R; Tozawa K; Watanuki S; Shimizu T; Mitsuhashi T; Murata M; Okamoto S; Mori T
Rinsho Ketsueki; 2018; 59(8):997-1001. PubMed ID: 30185717
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease.
Taniguchi K; Shimazaki C; Fujimoto Y; Shimura K; Uchiyama H; Matsumoto Y; Kuroda J; Horiike S; Taniwaki M
Int J Hematol; 2009 Jul; 90(1):99-102. PubMed ID: 19554396
[TBL] [Abstract][Full Text] [Related]
11. [Tocilizumab treatment of HHV8-positive/HIV-negative, multricentric plasma cell type Castleman's disease].
Mûzes G; Csomor J; Sipos F
Magy Onkol; 2016 Nov; 60(4):328-332. PubMed ID: 27898752
[TBL] [Abstract][Full Text] [Related]
12. [Dyspnoea, cough and B symptoms in a 40-year-old woman].
Wolfensberger A; Benz R; Russi EW; Tinguely M; Keller C; Gerber B
Internist (Berl); 2013 Aug; 54(8):1011-5. PubMed ID: 23836253
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab.
Akiyama M; Yasuoka H; Takeuchi T
Ann Hematol; 2017 Dec; 96(12):2117-2119. PubMed ID: 28861599
[No Abstract] [Full Text] [Related]
14. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
Kawabata H; Tomosugi N; Kanda J; Tanaka Y; Yoshizaki K; Uchiyama T
Haematologica; 2007 Jun; 92(6):857-8. PubMed ID: 17550864
[TBL] [Abstract][Full Text] [Related]
15. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
Sun Y; Wang D; Salvadore G; Hsu B; Curran M; Casper C; Vermeulen J; Kent JM; Singh J; Drevets WC; Wittenberg GM; Chen G
Brain Behav Immun; 2017 Nov; 66():156-164. PubMed ID: 28676350
[TBL] [Abstract][Full Text] [Related]
16. Multicentric Castleman's disease associated with inherited epidermolysis bullosa.
Kawakami Y; Nishibu A; Kikuchi S; Ohtsuka M; Nakamura K; Nozawa Y; Abe M; Iwatsuki K; Kaneko F
J Dermatol; 2003 Sep; 30(9):689-93. PubMed ID: 14578560
[TBL] [Abstract][Full Text] [Related]
17. Comparison of IgG4-Related Lymphadenopathy and Multicentric Castleman's Disease: a Retrospective Study.
Sun C; Xu G; Lin J
Clin Lab; 2018 Oct; 64(10):1671-1678. PubMed ID: 30336525
[TBL] [Abstract][Full Text] [Related]
18. The Role of Interleukin-6 in Castleman Disease.
Yoshizaki K; Murayama S; Ito H; Koga T
Hematol Oncol Clin North Am; 2018 Feb; 32(1):23-36. PubMed ID: 29157617
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan.
Murakami M; Johkoh T; Hayashi S; Ohshima S; Mizuki M; Nakatsuka SI; Tomobe M; Kuroyanagi K; Nakasone A; Nishimoto N
Mod Rheumatol; 2020 Sep; 30(5):843-851. PubMed ID: 31829070
[No Abstract] [Full Text] [Related]
20. Multicentric Castleman disease presenting as a chylous pleural effusion.
Epstein D; Zohar Y; Ovadya D; Ammouri H; Kremer R; Lavi N; Tzoran I; Andrawas ER; Klein E; Miller A
Pathol Res Pract; 2020 Nov; 216(11):153209. PubMed ID: 32950896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
